Italian Real-Life Experience of Patients with Hereditary Transthyretin Amyloidosis Treated with Patisiran
Vincenzo Di Stefano,1 Antonella Fava,2 Luca Gentile,3 Pietro Guaraldi,4 Luca Leonardi,5 Loris Poli,6 Matteo Tagliapietra,7 Michele Vastola,8,9 Salvatore Fanara,1 Bruno Ferrero,10 Mauro Giorgi,2 Federico Perfetto,8 Massimo Russo,3 Domitilla Russo11 1Department of Biomedicine, Neuroscience and Advance...
Main Authors: | Di Stefano V, Fava A, Gentile L, Guaraldi P, Leonardi L, Poli L, Tagliapietra M, Vastola M, Fanara S, Ferrero B, Giorgi M, Perfetto F, Russo M, Russo D |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2022-05-01
|
Series: | Pharmacogenomics and Personalized Medicine |
Subjects: | |
Online Access: | https://www.dovepress.com/italian-real-life-experience-of-patients-with-hereditary-transthyretin-peer-reviewed-fulltext-article-PGPM |
Similar Items
-
Practical Guidance for the Use of Patisiran in the Management of Polyneuropathy in Hereditary Transthyretin-Mediated Amyloidosis
by: Dixon S, et al.
Published: (2023-11-01) -
Advances in the treatment of hereditary transthyretin amyloidosis: A review
by: Morie A. Gertz, et al.
Published: (2019-09-01) -
A phase II, open-label, extension study of long-term patisiran treatment in patients with hereditary transthyretin-mediated (hATTR) amyloidosis
by: Teresa Coelho, et al.
Published: (2020-07-01) -
A comparative analysis of international health technology assessments for novel gene silencing therapies: patisiran and inotersen
by: Sergio Iannazzo
Published: (2021-03-01) -
Trial design and rationale for APOLLO, a Phase 3, placebo-controlled study of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy
by: David Adams, et al.
Published: (2017-09-01)